To evaluate the impact of syntenin loss-of-function in cancer cells, we selected three different models: mouse melanoma B16F10 (mixture of spindle-shaped and epithelial-like cells, mutated for p53, RAS wild-type, highly metastatic and invasive), Human colorectal adenocarcinoma HT29 (epithelial cells, mutated for p53, RAS wild-type, highly metastatic, and invasive) and Human breast adenocarcinoma MCF7 (epithelial cells, ER-positive, p53, and RAS wild-type, non-metastatic, poorly invasive). Here, SDCBP is linked to cancer.